Literature DB >> 34515349

Molecular mechanisms involved in DNA repair in human cancers: An overview of PI3k/Akt signaling and PIKKs crosstalk.

Forough Alemi1, Aydin Raei Sadigh1, Faezeh Malakoti1, Yusuf Elhaei2, Seyed Hamed Ghaffari3, Masomeh Maleki1, Zatollah Asemi4, Bahman Yousefi1, Niloufar Targhazeh1, Maryam Majidinia5.   

Abstract

The cellular genome is frequently subjected to abundant endogenous and exogenous factors that induce DNA damage. Most of the Phosphatidylinositol 3-kinase-related kinases (PIKKs) family members are activated in response to DNA damage and are the most important DNA damage response (DDR) proteins. The DDR system protects the cells against the wrecking effects of these genotoxicants and repairs the DNA damage caused by them. If the DNA damage is severe, such as when DNA is the goal of chemo-radiotherapy, the DDR drives cells toward cell cycle arrest and apoptosis. Some intracellular pathways, such as PI3K/Akt, which is overactivated in most cancers, could stimulate the DDR process and failure of chemo-radiotherapy with the increasing repair of damaged DNA. This signaling pathway induces DNA repair through the regulation of proteins that are involved in DDR like BRCA1, HMGB1, and P53. In this review, we will focus on the crosstalk of the PI3K/Akt and PIKKs involved in DDR and then discuss current achievements in the sensitization of cancer cells to chemo-radiotherapy by PI3K/Akt inhibitors.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  DNA damage response; PI3K/Akt; malignancy; signaling pathway

Mesh:

Substances:

Year:  2021        PMID: 34515349     DOI: 10.1002/jcp.30573

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

Review 1.  Research Progress on the Anticancer Activities and Mechanisms of Polysaccharides From Ganoderma.

Authors:  Man Wang; Fei Yu
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

2.  The PIKK-AKT connection in the DNA damage response.

Authors:  Sejeong Shin; Katherine A Walker; Sang-Oh Yoon
Journal:  Sci Signal       Date:  2022-01-04       Impact factor: 9.517

3.  HMGB1 induces radioresistance through PI3K/AKT/ATM pathway in esophageal squamous cell carcinoma.

Authors:  Xueyuan Zhang; Naiyi Zou; Wenzhao Deng; Chunyang Song; Ke Yan; Wenbin Shen; Shuchai Zhu
Journal:  Mol Biol Rep       Date:  2022-10-19       Impact factor: 2.742

Review 4.  Development and Evolution of DNA-Dependent Protein Kinase Inhibitors toward Cancer Therapy.

Authors:  Yoshihisa Matsumoto
Journal:  Int J Mol Sci       Date:  2022-04-12       Impact factor: 6.208

Review 5.  DNA repair and damage pathways in mesothelioma development and therapy.

Authors:  Faezeh Malakoti; Niloufar Targhazeh; Erfan Abadifard; Reza Zarezadeh; Sahar Samemaleki; Zatollah Asemi; Simin Younesi; Reza Mohammadnejad; Seyed Hadi Hossini; Ansar Karimian; Forough Alemi; Bahman Yousefi
Journal:  Cancer Cell Int       Date:  2022-05-02       Impact factor: 6.429

Review 6.  From inflammatory bowel disease to colorectal cancer: what's the role of miRNAs?

Authors:  Mostafa Vaghari-Tabari; Niloufar Targhazeh; Soheila Moein; Durdi Qujeq; Forough Alemi; Maryam Majidina; Simin Younesi; Zatollah Asemi; Bahman Yousefi
Journal:  Cancer Cell Int       Date:  2022-04-11       Impact factor: 5.722

7.  Metformin Attenuates UVA-Induced Skin Photoaging by Suppressing Mitophagy and the PI3K/AKT/mTOR Pathway.

Authors:  Qiuyan Chen; Haiying Zhang; Yimeng Yang; Shuming Zhang; Jing Wang; Dawei Zhang; Huimei Yu
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

8.  In-silico molecular modelling, MM/GBSA binding free energy and molecular dynamics simulation study of novel pyrido fused imidazo[4,5-c]quinolines as potential anti-tumor agents.

Authors:  Upala Dasmahapatra; Chitluri Kiran Kumar; Soumyadip Das; Prathima Thimma Subramanian; Poornimaa Murali; Arnold Emerson Isaac; Karuppasamy Ramanathan; Balamurali Mm; Kaushik Chanda
Journal:  Front Chem       Date:  2022-09-30       Impact factor: 5.545

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.